{filename}

Publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Biofluid Biology of neoplasia Biomarker Analysis Biomarker Validation Biomarkers Bladder Brain Breast Cancer CDKN2A mutation Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparison study Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Profiling Gene Fusions Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-related Colitis Immuno-Oncology Immunotherapy Inflammation Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR pathway Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis PBMCs PCA Cell Lines PIK3CA mutation Placenta Plasma Platform Comparison Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate qNPA qPCR Radioimmunotherapy Rearrangements Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Carcinoma SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid Therapeutic Response Therapeutic targets TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Urothelial carcinoma VEGFR Xenograft Tissue

NGS-Based miRNA Profiling to Develop Signatures of Potential Clinical Applications

MicroRNAs — small, non-coding RNA molecules ranging from 18 to 25 nucleotides — have recently demonstrated potential as markers for diagnostic or prognostic applications due to their resilience to degradation, comprehensive annotation of more than 2,000 transcripts, and a deeper understanding of how miRNAs play a role in human disease. However, application of miRNA biomarkers has been limited by the difficulty of extracting quality product from clinically relevant sample types, the biases associated with preparing small, non-coding RNAs for next generation sequencing, and the data complexity caused by the sequencing of random fragments. 

In this online seminar, panelists will discuss two projects that are seeking to optimize miRNA profiling for eventual clinical applications. 

Speakers

Scott Tebbutt
Don Baldwin

Speaker Biographies

Scott Tebbutt, associate professor in the Department of Medicine at the University of British Columbia, will share his team's work developing tissue- and blood-based miRNA signatures of acute heart failure. Currently, there are no well-defined response biomarkers that can be used to monitor treatment or evaluate recovery in patients with severe inotrope-dependent acute heart failure. Dr. Tebbutt will present details from a study that is characterizing miRNAs as tissue and circulating biomarkers of heart failure in these patients over the first 30 days of medical management or mechanical circulatory support.  Scott Tebbutt is an associate professor in the Department of Medicine at the University of British Columbia. He is also chief scientific officer of the Prevention of Organ Failure (PROOF) Centre of Excellence — a not-for-profit organization dedicated to moving research findings into health care, and focused on non-invasive biomarkers that can diagnose and/or predict organ failure (heart, lung and kidney). His responsibilities include the evaluation of new, high-performance technologies to improve biomarker discovery, as well as computational biology approaches to better deal with cell type heterogeneity, and to allow integration of different omics data sets. Dr. Tebbutt holds a BA in biochemistry from the University of Oxford and a PhD in molecular genetics from the University of East Anglia (Cambridge Laboratory, John Innes Centre).

Don Baldwin, co-founder and chief scientific officer of MSK/dx, will discuss a project that is exploring miRNA profiling to identify biomarkers associated with bone fractures, with the goal of developing tests to help reduce the comorbidities and costs of treating complicated fracture cases. Dr. Baldwin will introduce a Latin square set of synthetic miRNAs developed by the Association of Biomolecular Resource Facilities that was used to demonstrate quantitative responses and specificity of the HTG EdgeSeq platform. The MSK/dx team then performed molecular profiling with the HTG EdgeSeq system to study circulating miRNAs in whole blood and serum from orthopedic trauma patients. 
 

Return To List